Nesyrgy (Amlodipine Besilate, Nebivolol Hydrochloride)

Nesyrgy combines a calcium‑channel blocker and a beta‑blocker to manage hypertension.

• Primary hypertension: lowers systolic and diastolic blood pressure in adults with essential hypertension.
• Secondary hypertension: contributes to blood‑pressure control when an underlying cause has been identified and treated.
• Hypertension requiring combination therapy: provides additive blood‑pressure reduction for patients who need more than one agent to achieve target levels.

• Amlodipine besilate blocks L‑type calcium channels in vascular smooth muscle, causing vasodilation and reduced peripheral resistance. Nebivolol hydrochloride selectively antagonises β1‑adrenergic receptors, decreasing heart rate and contractility, while also stimulating endothelial nitric‑oxide release for additional vasodilation. The combined actions result in a synergistic reduction of arterial pressure.

Adverse reactions may occur with any antihypertensive therapy.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness, especially after standing.
• Fatigue: general feeling of tiredness.
• Flushing: transient warmth and redness of the skin.
• Nausea: occasional upset stomach.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Bradycardia: abnormally slow heart rate.
• Hepatic dysfunction: elevated liver enzymes.
• Allergic reactions: rash, itching, or swelling of face/lips.
• Heart failure exacerbation: worsening shortness of breath.
• Angio‑edema: rapid swelling of lips, tongue, or throat.

Patients should be evaluated for cardiovascular and hepatic status before initiating therapy.

• Assess baseline blood pressure: ensure appropriate starting level.
• Review cardiac history: avoid in uncontrolled heart failure.
• Monitor liver function: periodic tests recommended.
• Caution in elderly: start at lower dose to reduce orthostatic effects.
• Avoid abrupt discontinuation: taper under medical supervision.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Drug‑interaction potential should be reviewed before prescribing.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels.
• Non‑dihydropyridine calcium‑channel blockers (e.g., verapamil, diltiazem): additive negative inotropic effect.
• Other beta‑blockers: risk of excessive bradycardia and hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance hypotensive effect.

• Antihyperglycemics: may mask hypoglycaemia symptoms.
• NSAIDs: can reduce antihypertensive efficacy.
• Lithium: may increase lithium concentrations.
• Alcohol: can potentiate dizziness and hypotension.